BioNTech SE (BSP:B1NT34) Total Stockholders Equity: R$104,829 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:B1NT34 BioNTech SE BSP:B1NT34
50 GF Score
Price R$30.24
GF Value R$27.39
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is BioNTech SE Total Stockholders Equity?

BioNTech SE BSP:B1NT34 +1.31% 50 Total Stockholders Equity is R$104,829 Mil as of Jun. 2026. GuruFocus rates BSP:B1NT34 with a GF Score™ of 50/100 and a GF Value™ of R$27.39 (Fairly Valued). The stock has 4 warning signs investors should review.

BioNTech SE's Total Stockholders Equity for the quarter that ended in Jun. 2026 was R$104,829 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. BioNTech SE's Book Value per Share for the quarter that ended in Jun. 2026 was R$26.08. The ratio of a company's debt over equity can be used to measure how leveraged this company is. BioNTech SE's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.02.

BioNTech SE  (BSP:B1NT34) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

BioNTech SE's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(104828.578-0)/4019.270
=26.08

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

BioNTech SE's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(337.671 + 1528.375) / 104828.578
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNTech SE Total Stockholders Equity Related Terms

BioNTech SE Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for BioNTech SE's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNTech SE Total Stockholders Equity Chart

BioNTech SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 75,997.38 111,440.30 108,179.78 124,007.46 122,812.02

BioNTech SE Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 118,368.61 116,307.23 122,812.02 113,042.79 104,828.58
BSP:B1NT34
50GF Score
BioNTech SE BSP:B1NT34
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of R$104,829 Mil mean?
BioNTech SE (BSP:B1NT34) has a Total Stockholders Equity of R$104,829 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for BioNTech SE and its competitors.
Is BioNTech SE's Total Stockholders Equity too high?
BioNTech SE's current Total Stockholders Equity is R$104,829 Mil. Overall, BioNTech SE has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's Total Stockholders Equity compare to INSM and INCY?
BioNTech SE's Total Stockholders Equity of R$104,829 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for BioNTech SE and its competitors. BioNTech SE's current Total Stockholders Equity is R$104,829 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BSP:B1NT34) is currently considered Fairly Valued. The stock's GF Value™ is R$27.39, compared to a current price of R$30.24 — trading 10.4% above its estimated fair value. The current Total Stockholders Equity is R$104,829 Mil. BioNTech SE's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For BioNTech SE (BSP:B1NT34), the current Total Stockholders Equity is R$104,829 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioNTech SE (BSP:B1NT34) Overvalued in 2026?

Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued. The current stock price of R$30.24 is trading 10.4% above its estimated GF Value™ of R$27.39. GuruFocus considers BioNTech SE to be Fairly Valued.

Key valuation signals for BSP:B1NT34:

  • Total Stockholders Equity: R$104,829 Mil
  • GF Value™: R$27.39 vs. price of R$30.24 (10.4% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the BSP:B1NT34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioNTech SE Business Description

Address An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
50GF Score

Get the complete analysis for BSP:B1NT34

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$30.24
Price
R$27.39
GF Value